Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug.

Oblimersen sodium (Genasense™) is an antisense oligodeoxynucleotide specific for the antiapoptotic protein Bcl-2, which could enhance the sensitivity of leukemic cells to chemotherapy in this ...

Stoke Therapeutics, Inc. STOK announced that the FDA has granted a Breakthrough Therapy designation to its investigational ...

antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA ...

The oligonucleotides market has gained significant traction in recent years due to its critical role in molecular biology, genetics, and therapeutics. Oligonucleotides, short DNA or RNA molecules, are ...